Trial Profile
A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin degludec/liraglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DUAL VI; DUAL VI-Easy Titration
- Sponsors Novo Nordisk
- 23 Jan 2019 According to a Novo Nordisk media release, Xultophy was approved by Health Canada in April 2018 based on data from the DUAL clinical development program.
- 16 Sep 2016 Primary endpoint (Change from baseline in HbA1c) has been met, according to results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes